Table 2.
Genotype not included in quadrivalent and nonavalent vaccines at oral and genital sites. Frequencies are indicated in brackets. Significant and most frequent genotypes in groups are marked with an asterisk.
| HPV+ (Oral) (n = 34) | HPV+ (Genital) (n = 248) | |||
|---|---|---|---|---|
| Genotypes Not Included in Quadrivalent or Nonavalent Vaccine | % (n) | L/H Risk | % (n) | L/H Risk |
| 3 | 2.9 (1) | LR | - | |
| 7 | 2.9 (1) | LR | - | |
| 10 | 2.9 (1) | LR | - | |
| 35 | - | - | 2.0 (5) | HR |
| 39 | - | - | 3.2 (8) | HR |
| 40 | - | - | 0.8 (2) | LR |
| 42 | - | - | 8.9 (22) * | LR |
| 44 | - | - | 3.6 (9) | LR |
| 51 | 8.8 (3) | HR | 9.3 (23) * | HR |
| 53 | 5.9 (2) | HR | 11.3 (28) * | HR |
| 54 | 2.9 (1) | LR | 3.2 (8) | LR |
| 55 | - | - | 0.4 (1) | LR |
| 56 | 5.9 (2) | HR | 4.8 (12) | HR |
| 59 | 2.9 (1) | HR | 3.6 (9) | HR |
| 61 | 2.9 (1) | LR | 2.0 (5) | LR |
| 62 | 2.9 (1) | LR | 2.8 (7) | LR |
| 64 | - | - | 0.4 (1) | HR |
| 66 | 8.8 (3) | HR | 12.9 (32) * | HR |
| 67 | - | - | 1.6 (4) | HR |
| 68 | - | - | 6.0 (15) * | HR |
| 69 | - | - | 0.4 (1) | HR |
| 70 | - | - | 3.2 (8) | HR |
| 72 | - | - | 0.8 (2) | LR |
| 73 | - | - | 4.0 (10) | HR |
| 74 | - | - | 1.2 (3) | LR |
| 81 | - | - | 2.4 (6) | LR |
| 82 | - | - | 0.8 (2) | HR |
| 83 | 2.9 (1) | LR | 2.0 (5) | LR |
| 84 | - | - | 2.8 (7) | LR |
| 87 | - | - | 0.4 (1) | LR |
| 89 | - | - | 2.8 (7) | LR |
| 107 | 5.9 (2) | LR | - | - |